Pharmacokinetics, Safety, and Efficacy of Acalabrutinib in Chinese Patients with Relapsed/Refractory Mantle Cell Lymphoma and Other B-Cell Malignancies: An Open-Label, Multicenter Phase 1/2 Trial

被引：1

作者：

Zhu, Jun ^{[1
]}

Song, Yuqin ^{[1
]}

Li, Jianyong ^{[2
]}

Zhou, Keshu ^{[3
]}

Ke, Xiaoyan ^{[4
]}

Cai, Zhen ^{[5
]}

Zhang, Huilai ^{[6
]}

Yao, Tingting ^{[7
]}

Xia, Zhen ^{[7
]}

Wang, Yiqiu ^{[7
]}

Lai, Peiqiong ^{[7
]}

Liu, Xiaofeng ^{[7
]}

机构：

[1] Peking Univ Canc Hosp & Inst, Dept Lymphoma, Minist Educ, Key Lab Carcinogenesis & Translat Res, Beijing, Peoples R China

[2] Nanjing Med Univ, Affiliated Hosp 1, Nanjing, Peoples R China

[3] Zhengzhou Univ, Affiliated Canc Hosp, Henan Canc Hosp, Zhengzhou, Peoples R China

[4] Peking Univ Third Hosp, Dept Hematol, Beijing, Peoples R China

[5] Zhejiang Univ, Affiliated Hosp 1, Med Coll, Dept Hematol, Hangzhou, Peoples R China

[6] Tianjin Med Univ Canc Inst & Hosp, Tianjin, Peoples R China

[7] AstraZeneca, Shanghai, Peoples R China

来源：

关键词：

D O I：

10.1182/blood-2022-157057

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：6496 / 6497

页数：2